Dupilumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Dupilumab (DB12159): No TxGNN Repurposing Predictions Available
One-Sentence Summary
Dupilumab (Dupixent) is a biologic monoclonal antibody targeting the IL-4Rα receptor, used to treat type 2 inflammatory conditions including atopic dermatitis and asthma. The current Evidence Pack contains no TxGNN repurposing predictions, as critical input data — including mechanism of action, original indications, and safety information — were not successfully loaded. A meaningful repurposing evaluation cannot proceed until these data gaps are resolved.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Data not loaded (atopic dermatitis / type 2 inflammatory disease per public sources) |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — model produced no output |
| Italy Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Data Gap Summary
The Evidence Pack was generated with only one confirmed input (drugbank), and two blocking gaps were flagged at creation time:
| Gap ID | Category | Missing Item | Severity | Impact |
|---|---|---|---|---|
| DG001 | Drug Level | Package insert warnings / contraindications | Blocking | Cannot proceed to safety pre-screening (S1) |
| DG002 | Drug Level | Mechanism of action (MOA) | High | Mechanistic relevance analysis unavailable |
Because predicted_indications is empty, all downstream sections (clinical trial evidence, literature evidence, mechanism analysis) cannot be generated.
Safety Considerations
Please refer to the package insert for safety information. No drug-drug interaction data was found for Dupilumab in the queried sources.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline returned zero repurposing candidates for Dupilumab, most likely because the model's required inputs — including MOA graph embeddings and original indication labels — were absent from the Evidence Pack. No evidence review is possible without a valid prediction set.
To proceed, the following is needed:
- Re-run TxGNN prediction with complete drug node data (MOA, DrugBank categories, known indication labels)
- Load package insert (TFDA/EMA/FDA) to extract approved indications, warnings, and contraindications
- Confirm DrugBank MOA: Dupilumab is an IL-4Rα antagonist (blocks IL-4 and IL-13 signaling); this should be retrievable via DrugBank API (DB12159)
- Verify Italy (AIFA) / Taiwan (TFDA) marketing authorisation status — both currently show 0 licences, which may be a data retrieval issue rather than true non-approval
- Once predictions are available, re-generate Evidence Pack v5 and re-run this report
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.